Article
CircIFNGR2 enhances proliferation and migration of CRC and induces cetuximab resistance by indirectly targeting KRAS via sponging to MiR-30b.
Cell death & disease - 13 Jan 2023
Zhang Qi, Zheng Yifeng, Liu Jiajia, Tang Xiaoxiao, Wang Yuan, Li Xianzheng, Li Huibin, Zhou Xiaoying, Tang Shiru, Tang Yitao, Wang Xiaoyan, He Han, Li Tingting
Abstract excerpt
Currently the clinical efficacy of colorectal cancer (CRC) which is the most common malignant tumors over the world has not reached an ideal level. Cetuximab, the monoclonal antibody targeting the extracellular domain of EGFR, has shown its great efficacy in the promotion of apoptosis and the inhibition of tumor cells-like characteristics in numerous cancers. However certain KRAS wild-type CRC patients...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.